We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$980M
AUM Growth
+$260M
Cap. Flow
+$316M
Cap. Flow %
32.2%
Top 10 Hldgs %
50.1%
Holding
93
New
25
Increased
16
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$25.5M
2
GLUE icon
Monte Rosa Therapeutics
GLUE
+$18.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.9M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$16.5M
5
IMNM icon
Immunome
IMNM
+$16.1M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$14.2M
2
CGON icon
CG Oncology
CGON
+$11M
3
VRDN icon
Viridian Therapeutics
VRDN
+$10.8M
4
PFE icon
Pfizer
PFE
+$10.4M
5
AVTX icon
Avalo Therapeutics
AVTX
+$9.52M

Sector Composition

Rank Sector Weight
1 Healthcare 85.36%
2 Financials 1.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
26
Immunovant
IMVT
$8.64B
$10.3M 1.05%
+414,236
New +$10.7M
SYRE icon
27
Spyre Therapeutics
SYRE
$8.98B
$9.41M 0.96%
186,618
-1,119
-0.6% -$42.2K
BIIB icon
28
Biogen
BIIB
$31.1B
$9.34M 0.95%
50,967
-24,445
-32% -$4.5M
GH icon
29
Guardant Health
GH
$21.4B
$9.1M 0.93%
98,514
+6,600
+7% +$663K
PCVX icon
30
Vaxcyte
PCVX
$8.76B
$8.42M 0.86%
144,981
-3,806
-3% -$207K
QURE icon
31
CALL
uniQure
QURE
$3.26B
$8.18M 0.83%
500,000
-220,800
-31% -$4.47M
SVRA icon
32
Savara
SVRA
$1.08B
$7.81M 0.8%
+1,430,982
New +$7.97M
BNTC icon
33
Benitec Biopharma
BNTC
$431M
$7.64M 0.78%
717,725
-13,992
-2% -$162K
SNDX icon
34
CALL
Syndax Pharmaceuticals
SNDX
$1.7B
$7.48M 0.76%
+320,000
New +$6.95M
ORKA
35
Oruka Therapeutics
ORKA
$7.16B
$7.4M 0.76%
+150,908
New +$5.24M
CGEN icon
36
Compugen
CGEN
$228M
$7.06M 0.72%
3,315,845
-163,960
-5% -$318K
CELC icon
37
CALL
Celcuity
CELC
$4.22B
$6.22M 0.63%
+54,500
New +$5.94M
TRVI icon
38
Trevi Therapeutics
TRVI
$2.59B
$6.1M 0.62%
511,127
-30,113
-6% -$337K
INSM icon
39
Insmed
INSM
$27.6B
$5.86M 0.6%
35,850
-35,406
-50% -$5.44M
VCYT icon
40
Veracyte
VCYT
$3.42B
$5.79M 0.59%
179,700
-177,858
-50% -$6.58M
CERS icon
41
Cerus
CERS
$572M
$5.78M 0.59%
3,176,547
+362,164
+13% +$789K
CLDX icon
42
Celldex Therapeutics
CLDX
$3.35B
$5.66M 0.58%
178,378
-12,696
-7% -$346K
CCCC icon
43
C4 Therapeutics
CCCC
$502M
$5.03M 0.51%
1,911,785
-82,439
-4% -$194K
CYTK icon
44
Cytokinetics
CYTK
$10.2B
$4.69M 0.48%
+71,203
New +$4.53M
CLYM
45
Climb Bio
CLYM
$846M
$4.69M 0.48%
+684,908
New +$3.95M
CMPX icon
46
Compass Therapeutics
CMPX
$407M
$4.54M 0.46%
859,049
-192,294
-18% -$1.11M
SRZN icon
47
Surrozen
SRZN
$279M
$4.2M 0.43%
144,255
-13,068
-8% -$313K
CTNM
48
Contineum Therapeutics
CTNM
$576M
$3.94M 0.4%
301,729
-5,811
-2% -$77.9K
ZURA icon
49
Zura Bio
ZURA
$540M
$3.34M 0.34%
+560,651
New +$3.39M
FULC icon
50
Fulcrum Therapeutics
FULC
$283M
$3.22M 0.33%
419,949
+25,299
+6% +$235K
1
2
3 4

Similar funds

MK
MASTERINVEST Kapitalanlage Vienna $962M AUM 27.59% 1-Year Est. Return
QIM
Quantitative Investment Management Charlottesville, Virginia $963M AUM 12.95% 1-Year Est. Return
TC
TwinBeech Capital Purchase, New York $965M AUM 0.23% 1-Year Est. Return
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
PO
Paradigm Operations San Francisco, California $954M AUM 20.29% 1-Year Est. Return

Silverarc Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Silverarc Capital Management held 93 positions worth $980M, up 36% from $720M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management deployed $316M of net new capital in Q1 2026, opening 25 new positions and adding to 16 existing holdings. Its largest new stake was Zenas BioPharma: 1,135,935 shares worth $22.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Abivax, an estimated $14.2M trimmed.

  • Silverarc Capital Management's largest Q1 2026 buy was Zenas BioPharma: 1,135,935 shares worth $22.2M.
  • Silverarc Capital Management added most to Monte Rosa Therapeutics in Q1 2026, an estimated $18.6M increase.
  • Silverarc Capital Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $14.2M.
  • Silverarc Capital Management fully exited Viridian Therapeutics in Q1 2026, selling an estimated $10.8M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $980M portfolio in Q1 2026.
  • Silverarc Capital Management opened 25 new positions and closed 20 in Q1 2026.
  • Silverarc Capital Management's portfolio value rose 36% quarter-over-quarter to $980M.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.